The Food and Drug Administration has authorized certain Zyn nicotine pouches to be marketed as presenting lower health risks than cigarettes. The decision allows manufacturers to make comparative claims about these products to consumers.
Nicotine pouches are small packets placed between the gum and lip that release nicotine without smoke or the need to spit. They come in various flavors and have grown significantly in popularity, particularly among young people. The products contain no tobacco but deliver nicotine, avoiding the tar and carcinogens produced by burning cigarettes.
Public health experts have expressed mixed reactions to the FDA's decision. Many acknowledge that nicotine pouches can serve as a harm reduction tool for current smokers trying to move away from combustible tobacco. Research suggests the pouches carry substantially lower health risks than cigarettes and may be less harmful than e-cigarettes.
However, significant concerns remain about youth adoption. Recent British research published in the Lancet Public Health found that nicotine pouch use among 16- to 24-year-olds jumped from 0.7% in 2022 to 4% in 2025. Overall use in Great Britain rose from 0.1% in 2020 to 1% in 2025, representing about 522,000 people. The sharpest increases occurred among young men.
Dr. Harry Tattan-Birch, lead author of the British research, attributed the growth to "aggressive advertising targeting this group on social media, billboards, in bars and train stations, and through sponsorships of motorsports and music festivals." He emphasized that while pouches pose lower risks than cigarettes, they remain "not harmless."
A troubling finding from the research showed that 16% of pouch users had never regularly smoked, suggesting the products are attracting people who would not otherwise use nicotine. Additionally, more than two-thirds of users also consumed other nicotine products, indicating concurrent use rather than replacement of cigarettes.
Public health advocates warn that marketing these products as lower risk could inadvertently appeal to adolescents and young adults who might not otherwise develop nicotine addiction. Caroline Cerny, deputy chief executive of Ash, called the marketing "heavy and indiscriminate," noting that "they shouldn't be used by children or people who don't already smoke, due to the addictive nature of nicotine."
Researchers stressed the importance of implementing age-of-sale legislation, advertising restrictions, and regulations on flavors, packaging, and nicotine content. The FDA continues balancing harm reduction for current smokers against preventing youth initiation of nicotine use as it evaluates tobacco products based on their broader public health impact.